Antiangiogenic Therapy for Diabetic Nephropathy

Area of Science:

• Nephrology
• Vascular Biology
• Endocrinology

Background:

• Diabetic nephropathy involves abnormal angiogenesis, primarily mediated by vascular endothelial growth factor (VEGF).
• While anti-VEGF therapies show benefits, complete blockade can cause proteinuria and renal thrombotic microangiopathy, highlighting the need for balanced VEGF modulation.
• Effective antiangiogenic therapy must reduce excessive glomerular angiogenesis without causing endothelial injury.

Purpose of the Study:

• To explore therapeutic strategies for early diabetic nephropathy focusing on controlled antiangiogenesis.
• To evaluate the potential of endogenous antiangiogenic factors, such as vasohibin-1, endostatin, and tumstatin, as safer alternatives to VEGF blockade.

Main Methods:

• Review of animal experiments and clinical evidence on angiogenesis in diabetic nephropathy.
• Investigation of the mechanisms of action for endogenous antiangiogenic factors.
• Assessment of the effects of these factors on albuminuria and glomerular alterations in a diabetic mouse model.

Main Results:

• Endogenous antiangiogenic factors like endostatin and tumstatin inhibit endothelial cell overactivation.
• Vasohibin-1, an endothelium-derived factor, enhances endothelial cell survival and stress tolerance while curbing excess angiogenesis.
• These factors demonstrated suppression of albuminuria and glomerular damage in a diabetic mouse model.

Conclusions:

• Antiangiogenic therapy for diabetic nephropathy requires precise control to eliminate excessive angiogenesis without harming endothelial cells.
• Endogenous factors like vasohibin-1 offer a promising therapeutic avenue for improving renal outcomes in early diabetic nephropathy.
• Targeting specific antiangiogenic pathways may represent a safer and more effective strategy than broad VEGF blockade.